

ASX/Media Release

14 November 2017

Results of Annual General Meeting

Perth 14 November 2017: Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or the “Company”) advises that the Annual General Meeting of the Company was held today, 14 November 2017. All resolutions put to the meeting were passed on a show of hands. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the resolutions and the proxies received in respect of each resolution are set out below:

Resolutions		For	Against	At Proxy Holders Discretion	Abstain/ Excluded
1	Adoption of Remuneration Report (non-binding)	76,108,512	169,693	711,291	89,398,537
2	Re-election of Director –Mr Graham Griffiths	165,629,002	47,740	711,291	-
3	Approval of 10% Placement Capacity	164,498,595	1,071,738	711,291	106,409

About Botanix Pharmaceuticals

Botanix Pharmaceuticals is a clinical stage medical dermatology company, which is dedicated to developing next generation therapeutics for the treatment of serious skin diseases. Our mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed, or are treated with therapeutics that are burdened with side effects profiles. Botanix is harnessing the untapped potential of a synthetic active pharmaceutical ingredient, known as cannabidiol, which has a well-established safety profile. Botanix has successfully completed its first-in-man studies with BTX 1503 and is currently conducting a follow-on clinical trial with acne patients in 2H 2017. The Company has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases and plans to progress the development of BTX 1503 for acne and its pipeline of other Permetrex™ enabled products alone, or in collaboration with partners.

For more information on Botanix, please visit www.botanixpharma.com or follow us on Twitter @Botanixpharma.

For more information, please contact:

General enquiries

Matt Callahan
Botanix Pharmaceuticals Ltd
Executive Director
P: +1 215 767 4184
E: mcallahan@botanixpharma.com

Investor Relations

Joel Seah
Vesparum Capital
P: +61 3 8542 4800
E: botanixpharma@vesparum.com

Media enquiries

Harrison Polites
MC Partners
P: +61 409 623 618
E: harrison.polites@mcpartners.com.au